الفهرس 
General IntroductionOnly 14 pages are availabe for public view
 |  | from | 186 |  |  |
| | | from | 186 | | |
Abstract
Skeletal muscle drugs (SMDs) are a wide group of medication and are used to treat different musculoskeletal disorders. These disorders include all forms of ill-health ranging from light, transitory disorders (e.g. traumatic pain, strains, sprains, post operative pain) to irreversible, chronic injuries (e.g. spasticity, neurological disorders, rheumatoid arthritis). SMDs can be divided into two main groups: analgesics and skeletal muscle relaxants. Some biopharmaceutical problems may appear during or after marketing and consequently, they affect patient compliance. Such as poor bioavailability (insufficient pain control), and intolerable side effects related to drug pharmacokinetics (short plasma half-life, and rapid plasma peaking) both can affect patient compliance. Pharmaceutical formulator takes over a great role to improve patient compliance. This can be done by either improving rate of dissolution of poorly soluble drugs or controlling drug release rate.